Omid C.  Farokhzad net worth and biography

Omid Farokhzad Biography and Net Worth

of Seer
Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 175 papers and is an inventor of over 200 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.

How old is Omid C. Farokhzad?

Dr. Farokhzad is currently 55 years old. There are 1 older executives and no younger executives at Seer. The oldest executive at Seer is Mr. David R. Horn, President,Treasurer & CFO, who is 57 years old. Learn More on Omid C. Farokhzad's age.

How do I contact Omid C. Farokhzad?

The corporate mailing address for Dr. Farokhzad and other Seer executives is , , . Seer can also be reached via phone at 650-453-0000 and via email at [email protected]. Learn More on Omid C. Farokhzad's contact information.

Has Omid C. Farokhzad been buying or selling shares of Seer?

Omid C. Farokhzad has not been actively trading shares of Seer during the past quarter. Learn More on Omid C. Farokhzad's trading history.

Who are Seer's active insiders?

Seer's insider roster includes Omid Farokhzad (), David Horn (CFO), and Omead Ostadan (COO). Learn More on Seer's active insiders.

Are insiders buying or selling shares of Seer?

During the last twelve months, Seer insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $98,000.00. During the last twelve months, insiders at the sold shares 5 times. They sold a total of 78,799 shares worth more than $152,501.27. The most recent insider tranaction occured on March, 7th when CEO Omid Farokhzad sold 52,857 shares worth more than $107,299.71. Insiders at Seer own 15.0% of the company. Learn More about insider trades at Seer.

Information on this page was last updated on 3/7/2024.

Omid C. Farokhzad Insider Trading History at Seer

See Full Table

Omid C. Farokhzad Buying and Selling Activity at Seer

This chart shows Dr. Omid C. Farokhzad's buying and selling at Seer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seer Company Overview

Seer logo
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.90
Low: $1.87
High: $2.00

50 Day Range

MA: $1.79
Low: $1.54
High: $2.09

2 Week Range

Now: $1.90
Low: $1.46
High: $5.65

Volume

384,227 shs

Average Volume

608,117 shs

Market Capitalization

$123.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63